Ranger, A.
Dunlop, A.
Hansen, V.N.
Princewill, G.
Landeg, S.
Donovan, E.M.
Harris, E.J.
McNair, H.A.
Haviland, J.
Kirby, A.M.
(2022). A Randomised Phase II Clinical Trial Comparing the Deliverability and Acute Toxicity of Wide Tangent versus Volumetric Modulated Arc Therapy to the Breast and Internal Mammary Chain. Clinical oncology,
.
Thiruchelvam, P.T.
Leff, D.R.
Godden, A.R.
Cleator, S.
Wood, S.H.
Kirby, A.M.
Jallali, N.
Somaiah, N.
Hunter, J.E.
Henry, F.P.
Micha, A.
O'Connell, R.L.
Mohammed, K.
Patani, N.
Tan, M.L.
Gujral, D.
Ross, G.
James, S.E.
Khan, A.A.
Rusby, J.E.
Hadjiminas, D.J.
MacNeill, F.A.
PRADA Trial Management Group,
(2022). Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study. The lancet. oncology,
.
show abstract
Background
Radiotherapy before mastectomy and autologous free-flap breast reconstruction can avoid adverse radiation effects on healthy donor tissues and delays to adjuvant radiotherapy. However, evidence for this treatment sequence is sparse. We aimed to explore the feasibility of preoperative radiotherapy followed by skin-sparing mastectomy and deep inferior epigastric perforator (DIEP) flap reconstruction in patients with breast cancer requiring mastectomy.
Methods
We conducted a prospective, non-randomised, feasibility study at two National Health Service trusts in the UK. Eligible patients were women aged older than 18 years with a laboratory diagnosis of primary breast cancer requiring mastectomy and post-mastectomy radiotherapy, who were suitable for DIEP flap reconstruction. Preoperative radiotherapy started 3-4 weeks after neoadjuvant chemotherapy and was delivered to the breast, plus regional nodes as required, at 40 Gy in 15 fractions (over 3 weeks) or 42·72 Gy in 16 fractions (over 3·2 weeks). Adverse skin radiation toxicity was assessed preoperatively using the Radiation Therapy Oncology Group toxicity grading system. Skin-sparing mastectomy and DIEP flap reconstruction were planned for 2-6 weeks after completion of preoperative radiotherapy. The primary endpoint was the proportion of open breast wounds greater than 1 cm width requiring a dressing at 4 weeks after surgery, assessed in all participants. This study is registered with ClinicalTrials.gov, NCT02771938, and is closed to recruitment.
Findings
Between Jan 25, 2016, and Dec 11, 2017, 33 patients were enrolled. At 4 weeks after surgery, four (12·1%, 95% CI 3·4-28·2) of 33 patients had an open breast wound greater than 1 cm. One (3%) patient had confluent moist desquamation (grade 3). There were no serious treatment-related adverse events and no treatment-related deaths.
Interpretation
Preoperative radiotherapy followed by skin-sparing mastectomy and immediate DIEP flap reconstruction is feasible and technically safe, with rates of breast open wounds similar to those reported with post-mastectomy radiotherapy. A randomised trial comparing preoperative radiotherapy with post-mastectomy radiotherapy is required to precisely determine and compare surgical, oncological, and breast reconstruction outcomes, including quality of life.
Funding
Cancer Research UK, National Institute for Health Research..
Harris, E.
Sinnatamby, R.
O'Flynn, E.
Kirby, A.M.
Bamber, J.C.
(2021). A Cross-Machine Comparison of Shear-Wave Speed Measurements Using 2D Shear-Wave Elastography in the Normal Female Breast. Applied sciences-basel,
Vol.11
(20),
pp. ?-? (16).
Marta, G.N.
Ramiah, D.
Kaidar-Person, O.
Kirby, A.
Coles, C.
Jagsi, R.
Hijal, T.
Sancho, G.
Zissiadis, Y.
Pignol, J.-.
Ho, A.Y.
Cheng, S.H.
Offersen, B.V.
Meattini, I.
Poortmans, P.
(2021). The Financial Impact on Reimbursement of Moderately Hypofractionated Postoperative Radiation Therapy for Breast Cancer: An International Consortium Report. Clinical oncology,
Vol.33
(5),
pp. 322-330.
Obeng-Gyasi, S.
Coles, C.E.
Jones, J.
Sacks, R.
Lightowlers, S.
Bliss, J.M.
Brunt, A.M.
Haviland, J.S.
Kirby, A.M.
Kalinsky, K.
(2021). When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management. American society of clinical oncology educational book,
(41),
pp. e79-e89.
show abstract
In the care of patients with operable breast cancer, there has been a shift toward increasing use of neoadjuvant therapy. There are benefits to neoadjuvant therapy, such as monitoring for response, as well as an increased rate of breast conservation and reduction of potential morbidity associated with breast surgery, including axillary management. Among patients with highly proliferative tumors, such as HER2-positive or triple-negative breast cancer, those with residual disease are at higher risk of recurrence, which informs the recommended systemic therapy in the adjuvant setting. For instance, in patients with residual disease after neoadjuvant chemotherapy and HER2-targeted therapy, there is a role for adjuvant trastuzumab emtansine for those with residual disease at the time of surgery. The same holds true regarding the role of adjuvant capecitabine in patients with residual disease after neoadjuvant chemotherapy. With the added complexities of treating patients in the era of the COVID-19 outbreak, additional considerations are critical, including initiation of surgery within an appropriate time from completion of neoadjuvant therapy. National consensus guidelines on time to surgery must be developed to improve measurement and comparison across systems. In addition, there is emerging radiation treatment management research addressing a number of factors, including hypofractionation, role of proton beam therapy, safe omission of radiotherapy, and preoperative radiotherapy with or without drug combination. In this article, the multidisciplinary approach of treating patients with operable breast cancer is highlighted, with updates and future considerations described. .
Dahn, H.M.
Boersma, L.J.
de Ruysscher, D.
Meattini, I.
Offersen, B.V.
Pignol, J.-.
Aristei, C.
Belkacemi, Y.
Benjamin, D.
Bese, N.
Coles, C.E.
Franco, P.
Ho, A.
Hol, S.
Jagsi, R.
Kirby, A.M.
Marrazzo, L.
Marta, G.N.
Moran, M.S.
Nichol, A.M.
Nissen, H.D.
Strnad, V.
Zissiadis, Y.E.
Poortmans, P.
Kaidar-Person, O.
(2021). The use of bolus in postmastectomy radiation therapy for breast cancer: A systematic review. Critical reviews in oncology/hematology,
Vol.163,
pp. 103391-103391.
de Mol van Otterloo, S.R.
Christodouleas, J.P.
Blezer, E.L.
Akhiat, H.
Brown, K.
Choudhury, A.
Eggert, D.
Erickson, B.A.
Daamen, L.A.
Faivre-Finn, C.
Fuller, C.D.
Goldwein, J.
Hafeez, S.
Hall, E.
Harrington, K.J.
van der Heide, U.A.
Huddart, R.A.
Intven, M.P.
Kirby, A.M.
Lalondrelle, S.
McCann, C.
Minsky, B.D.
Mook, S.
Nowee, M.E.
Oelfke, U.
Orrling, K.
Philippens, M.E.
Sahgal, A.
Schultz, C.J.
Tersteeg, R.J.
Tijssen, R.H.
Tree, A.C.
van Triest, B.
Tseng, C.-.
Hall, W.A.
Verkooijen, H.M.
(2021). Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. International journal of radiation oncology*biology*physics,
Vol.111
(4),
pp. 867-875.
Kaidar-Person, O.
Dahn, H.M.
Nichol, A.M.
Boersma, L.J.
de Ruysscher, D.
Meattini, I.
Pignol, J.-.
Aristei, C.
Belkacemi, Y.
Benjamin, D.
Bese, N.
Coles, C.E.
Franco, P.
Ho, A.Y.
Hol, S.
Jagsi, R.
Kirby, A.M.
Marrazzo, L.
Marta, G.N.
Moran, M.S.
Nissen, H.D.
Strnad, V.
Zissiadis, Y.
Poortmans, P.M.
Offersen, B.V.
(2021). A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer. Radiotherapy and oncology,
Vol.164,
pp. 115-121.
Settatree, S.
Dunlop, A.
Mohajer, J.
Brand, D.
Mooney, L.
Ross, G.
Gulliford, S.
Harris, E.
Kirby, A.
(2021). What Can Proton Beam Therapy Achieve for Patients with Pectus Excavatum Requiring Left Breast, Axilla and Internal Mammary Nodal Radiotherapy?. Clinical oncology,
Vol.33
(12),
pp. e570-e577.
Bhattacharya, I.S.
Haviland, J.S.
Turner, L.
Stobart, H.
Balasopoulou, A.
Stones, L.
Kirby, A.M.
Kirwan, C.C.
Coles, C.E.
Bliss, J.M.
PRIMETIME Trialists,
(2021). Can patient decision aids reduce decisional conflict in a de-escalation of breast radiotherapy clinical trial? The PRIMETIME Study Within a Trial implemented using a cluster stepped-wedge trial design. Trials,
Vol.22
(1),
pp. 397-?.
show abstract
Background
For patients with early breast cancer considered at very-low risk of local relapse, risks of radiotherapy may outweigh the benefits. Decisions regarding treatment omission can lead to patient uncertainty (decisional conflict), which may be lessened with patient decision aids (PDA). PRIMETIME (ISRCTN 41579286) is a UK-led biomarker-directed study evaluating omission of adjuvant radiotherapy in breast cancer; an embedded Study Within A Trial (SWAT) investigated whether PDA reduces decisional conflict using a cluster stepped-wedge trial design.
Methods
PDA diagrams and a video explaining risks and benefits of radiotherapy were developed in close collaboration between patient advocates and PRIMETIME trialists. The SWAT used a cluster stepped-wedge trial design, where each cluster represented the radiotherapy centre and referring peripheral centres. All clusters began in the standard information group (patient information and diagrams) and were randomised to cross-over to the enhanced information group (standard information plus video) at 2, 4 or 6 months. Primary endpoint was the decisional conflict scale (0-100, higher scores indicating greater conflict) which was assessed on an individual participant level. Multilevel mixed effects models used a random effect for cluster and a fixed effect for each step to adjust for calendar time and clustering. Robust standard errors were also adjusted for the clustering effect.
Results
Five hundred twenty-one evaluable questionnaires were returned from 809 eligible patients (64%) in 24 clusters between April 2018 and October 2019. Mean decisional conflict scores in the standard group (N = 184) were 10.88 (SD 11.82) and 8.99 (SD 11.82) in the enhanced group (N = 337), with no statistically significant difference [mean difference - 1.78, 95%CI - 3.82-0.25, p = 0.09]. Compliance with patient information and diagrams was high in both groups although in the enhanced group only 121/337 (36%) reported watching the video.
Conclusion
The low levels of decisional conflict in PRIMETIME are reassuring and may reflect the high-quality information provision, such that not everyone required the video. This reinforces the importance of working with patients as partners in clinical trials especially in the development of patient-centred information and decision aids..
Godden, A.R.
Micha, A.
Wolf, L.M.
Pitches, C.
Barry, P.A.
Khan, A.A.
Krupa, K.D.
Kirby, A.M.
Rusby, J.E.
(2021). Three-dimensional simulation of aesthetic outcome from breast-conserving surgery compared with viewing photographs or standard care: randomized clinical trial. British journal of surgery,
Vol.108
(10),
pp. 1181-1188.
show abstract
Abstract
Introduction
Over half of women with surgically managed breast cancer in the UK undergo breast-conserving treatment (BCT). While photographs are shown prior to reconstructive surgery or complex oncoplastic procedures, standard practice prior to breast conservation is to simply describe the likely aesthetic changes. Patients have expressed the desire for more personalized information about likely appearance after surgery. The hypothesis was that viewing a three-dimensional (3D) simulation improves patients’ confidence in knowing their likely aesthetic outcome after surgery.
Methods
A randomized, controlled trial of 117 women planning unilateral BCT was undertaken. The randomization was three-way: standard of care (verbal description alone, control group), viewing two-dimensional (2D) photographs, or viewing a 3D simulation before surgery. The primary endpoint was the comparison between groups’ median answer on a visual analogue scale (VAS) for the question administered before surgery: ‘How confident are you that you know how your breasts are likely to look after treatment?’
Results
The median VAS in the control group was 5.2 (i.q.r. 2.6–7.8); 8.0 (i.q.r. 5.7–8.7) for 2D photography, and 8.9 (i.q.r. 8.2–9.5) for 3D simulation. There was a significant difference between groups (P < 0.010) with post-hoc pairwise comparisons demonstrating a statistically significant difference between 3D simulation and both standard care and viewing 2D photographs (P < 0.010 and P = 0.012, respectively).
Conclusion
This RCT has demonstrated that women who viewed an individualized 3D simulation of likely aesthetic outcome for BCT were more confident going into surgery than those who received standard care or who were shown 2D photographs of other women. The impact on longer-term satisfaction with outcome remains to be determined.
Registration number: NCT03250260 (http://www.clinicaltrials.gov).
.
de Mol van Otterloo, S.R.
Christodouleas, J.P.
Blezer, E.L.
Akhiat, H.
Brown, K.
Choudhury, A.
Eggert, D.
Erickson, B.A.
Faivre-Finn, C.
Fuller, C.D.
Goldwein, J.
Hafeez, S.
Hall, E.
Harrington, K.J.
van der Heide, U.A.
Huddart, R.A.
Intven, M.P.
Kirby, A.M.
Lalondrelle, S.
McCann, C.
Minsky, B.D.
Mook, S.
Nowee, M.E.
Oelfke, U.
Orrling, K.
Sahgal, A.
Sarmiento, J.G.
Schultz, C.J.
Tersteeg, R.J.
Tijssen, R.H.
Tree, A.C.
van Triest, B.
Hall, W.A.
Verkooijen, H.M.
(2020). The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Frontiers in oncology,
Vol.10,
pp. 1328-?.
show abstract
Purpose: MR-guided Radiation Therapy (MRgRT) allows for high-precision radiotherapy under real-time MR visualization. This enables margin reduction and subsequent dose escalation which may lead to higher tumor control and less toxicity. The Unity MR-linac (Elekta AB, Stockholm, Sweden) integrates a linear accelerator with a 1.5T diagnostic quality MRI and an online adaptive workflow. A prospective international registry was established to facilitate the evidence-based implementation of the Unity MR-linac into clinical practice, to systemically evaluate long-term outcomes, and to aid further technical development of MR-linac-based MRgRT. Methods and Results: In February 2019, the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-linac study (MOMENTUM) started within the MR-linac Consortium. The MOMENTUM study is an international academic-industrial partnership between several hospitals and industry partner Elekta. All patients treated on the MR-linac are eligible for inclusion in MOMENTUM. For participants, we collect clinical patient data (e.g., patient, tumor, and treatment characteristics) and technical patient data which is defined as information generated on the MR-linac during treatment. The data are captured, pseudonymized, and stored in an international registry at set time intervals up to two years after treatment. Patients can choose to provide patient-reported outcomes and consent to additional MRI scans acquired on the MR-linac. This registry will serve as a data platform that supports multicenter research investigating the MR-linac. Rules and regulations on data sharing, data access, and intellectual property rights are summarized in an academic-industrial collaboration agreement. Data access rules ensure secure data handling and research integrity for investigators and institutions. Separate data access rules exist for academic and industry partners. This study is registered at ClinicalTrials.gov with ID: NCT04075305 (https://clinicaltrials.gov/ct2/show/NCT04075305). Conclusion: The multi-institutional MOMENTUM study has been set up to collect clinical and technical patient data to advance technical development, and facilitate evidenced-based implementation of MR-linac technology with the ultimate purpose to improve tumor control, survival, and quality of life of patients with cancer..
Townend, C.
Landeg, S.
Thorne, R.
Kirby, A.M.
McNair, H.A.
(2020). A review of permanent marking for radiotherapy in the UK. Radiography,
Vol.26
(1),
pp. 9-14.
Vasmel, J.E.
Charaghvandi, R.K.
Houweling, A.C.
Philippens, M.E.
van Asselen, B.
Vreuls, C.P.
van Diest, P.J.
van Leeuwen, A.M.
van Gorp, J.
Witkamp, A.J.
Koelemij, R.
Doeksen, A.
Sier, M.F.
van Dalen, T.
van der Wall, E.
van Dam, I.
Veldhuis, W.B.
Kirby, A.M.
Verkooijen, H.M.
van den Bongard, H.J.
(2020). Tumor Response After Neoadjuvant Magnetic Resonance Guided Single Ablative Dose Partial Breast Irradiation. International journal of radiation oncology*biology*physics,
Vol.106
(4),
pp. 821-829.
Murray Brunt, A.
Haviland, J.S.
Wheatley, D.A.
Sydenham, M.A.
Alhasso, A.
Bloomfield, D.J.
Chan, C.
Churn, M.
Cleator, S.
Coles, C.E.
Goodman, A.
Harnett, A.
Hopwood, P.
Kirby, A.M.
Kirwan, C.C.
Morris, C.
Nabi, Z.
Sawyer, E.
Somaiah, N.
Stones, L.
Syndikus, I.
Bliss, J.M.
Yarnold, J.R.
FAST-Forward Trial Management Group,
(2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet (london, england),
Vol.395
(10237),
pp. 1613-1626.
show abstract
Background We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after primary surgery for early breast cancer. Here, we present 5-year results of the FAST-Forward trial.Methods FAST-Forward is a multicentre, phase 3, randomised, non-inferiority trial done at 97 hospitals (47 radiotherapy centres and 50 referring hospitals) in the UK. Patients aged at least 18 years with invasive carcinoma of the breast (pT1-3, pN0-1, M0) after breast conservation surgery or mastectomy were eligible. We randomly allocated patients to either 40 Gy in 15 fractions (over 3 weeks), 27 Gy in five fractions (over 1 week), or 26 Gy in five fractions (over 1 week) to the whole breast or chest wall. Allocation was not masked because of the nature of the intervention. The primary endpoint was ipsilateral breast tumour relapse; assuming a 2% 5-year incidence for 40 Gy, non-inferiority was predefined as ≤1·6% excess for five-fraction schedules (critical hazard ratio [HR] of 1·81). Normal tissue effects were assessed by clinicians, patients, and from photographs. This trial is registered at isrctn.com, ISRCTN19906132.Findings Between Nov 24, 2011, and June 19, 2014, we recruited and obtained consent from 4096 patients from 97 UK centres, of whom 1361 were assigned to the 40 Gy schedule, 1367 to the 27 Gy schedule, and 1368 to the 26 Gy schedule. At a median follow-up of 71·5 months (IQR 71·3 to 71·7), the primary endpoint event occurred in 79 patients (31 in the 40 Gy group, 27 in the 27 Gy group, and 21 in the 26 Gy group); HRs versus 40 Gy in 15 fractions were 0·86 (95% CI 0·51 to 1·44) for 27 Gy in five fractions and 0·67 (0·38 to 1·16) for 26 Gy in five fractions. 5-year incidence of ipsilateral breast tumour relapse after 40 Gy was 2·1% (1·4 to 3·1); estimated absolute differences versus 40 Gy in 15 fractions were -0·3% (-1·0 to 0·9) for 27 Gy in five fractions (probability of incorrectly accepting an inferior five-fraction schedule: p=0·0022 vs 40 Gy in 15 fractions) and -0·7% (-1·3 to 0·3) for 26 Gy in five fractions (p=0·00019 vs 40 Gy in 15 fractions). At 5 years, any moderate or marked clinician-assessed normal tissue effects in the breast or chest wall was reported for 98 of 986 (9·9%) 40 Gy patients, 155 (15·4%) of 1005 27 Gy patients, and 121 of 1020 (11·9%) 26 Gy patients. Across all clinician assessments from 1-5 years, odds ratios versus 40 Gy in 15 fractions were 1·55 (95% CI 1·32 to 1·83, p<0·0001) for 27 Gy in five fractions and 1·12 (0·94 to 1·34, p=0·20) for 26 Gy in five fractions. Patient and photographic assessments showed higher normal tissue effect risk for 27 Gy versus 40 Gy but not for 26 Gy versus 40 Gy.Interpretation 26 Gy in five fractions over 1 week is non-inferior to the standard of 40 Gy in 15 fractions over 3 weeks for local tumour control, and is as safe in terms of normal tissue effects up to 5 years for patients prescribed adjuvant local radiotherapy after primary surgery for early-stage breast cancer.Funding National Institute for Health Research Health Technology Assessment Programme..
Meattini, I.
Andratschke, N.
Kirby, A.M.
Sviri, G.
Offersen, B.V.
Poortmans, P.
Kaidar Person, O.
(2020). Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm. Clinical and translational oncology,
Vol.22
(10),
pp. 1698-1709.
Vasmel, J.E.
Groot Koerkamp, M.L.
Kirby, A.M.
Russell, N.S.
Shaitelman, S.F.
Vesprini, D.
Anandadas, C.N.
Currey, A.
Keller, B.M.
Braunstein, L.Z.
Han, K.
Kotte, A.N.
de Waard, S.N.
Philippens, M.E.
Houweling, A.C.
Verkooijen, H.M.
van den Bongard, H.J.
(2020). Consensus on Contouring Primary Breast Tumors on MRI in the Setting of Neoadjuvant Partial Breast Irradiation in Trials. Practical radiation oncology,
Vol.10
(6),
pp. e466-e474.
Godden, A.R.
O'Connell, R.L.
Barry, P.A.
Krupa, K.C.
Wolf, L.M.
Mohammed, K.
Kirby, A.M.
Rusby, J.E.
(2020). 3-Dimensional objective aesthetic evaluation to replace panel assessment after breast-conserving treatment. Breast cancer (tokyo, japan),
Vol.27
(6),
pp. 1126-1136.
show abstract
Background Two-thirds of patients with early breast cancer undergo breast-conserving treatment (BCT). Aesthetic outcome is important and has long term implications for psychosocial wellbeing. The aesthetic goal of BCT is symmetry for which there is no gold-standard measure. Panel scoring is the most widely adopted assessment but has well-described limitations. This paper describes a model to objectively report aesthetic outcome using measures derived from 3-dimensional surface images (3D-SI).Method Objective measures and panel assessment were undertaken independently for 3D-SI of women who underwent BCT 1-5 years previously. Univariate analysis was used to test for association between measures and panel score. A forward stepwise multiple linear regression model was fitted to identify 3D measurements that jointly predicted the mean panel score. The fitted model coefficients were used to predict mean panel scores for an independent validation set then compared to the mean observed panel score.Results Very good intra-panel reliability was observed for the training and validation sets (wκ = 0.87, wκ = 0.84). Six 3D-measures were used in the multivariate model. There was a good correlation between the predicted and mean observed panel score in the training (n = 190) and validation (n = 100) sets (r = 0.68, r = 0.65). The 3D model tended to predict scores towards the median. The model was calibrated which improved the distribution of predicted scores.Conclusion A six-variable objective aesthetic outcome model for BCT has been described and validated. This can predict and could replace panel assessment, facilitating the independent and unbiased evaluation of aesthetic outcome to communicate and compare results, benchmark practice, and raise standards..
Nimalasena, S.
Gothard, L.
Anbalagan, S.
Allen, S.
Sinnett, V.
Mohammed, K.
Kothari, G.
Musallam, A.
Lucy, C.
Yu, S.
Nayamundanda, G.
Kirby, A.
Ross, G.
Sawyer, E.
Castell, F.
Cleator, S.
Locke, I.
Tait, D.
Westbury, C.
Wolstenholme, V.
Box, C.
Robinson, S.P.
Yarnold, J.
Somaiah, N.
(2020). Intratumoral Hydrogen Peroxide With Radiation Therapy in Locally Advanced Breast Cancer: Results From a Phase 1 Clinical Trial. International journal of radiation oncology, biology, physics,
Vol.108
(4),
pp. 1019-1029.
show abstract
Purpose Hydrogen peroxide (H 2 O 2 ) plays a vital role in normal cellular processes but at supraphysiological concentrations causes oxidative stress and cytotoxicity, a property that is potentially exploitable for the treatment of cancer in combination with radiation therapy (RT). We report the first phase 1 trial testing the safety and tolerability of intratumoral H 2 O 2 + external beam RT as a novel combination in patients with breast cancer and exploratory plasma marker analyses investigating possible mechanisms of action.Methods and materials Twelve patients with breast tumors ≥3 cm (surgically or medically inoperable) received intratumoral H 2 O 2 with either 36 Gy in 6 twice-weekly fractions (n = 6) or 49.5 Gy in 18 daily fractions (n = 6) to the whole breast ± locoregional lymph nodes in a single-center, nonrandomized study. H 2 O 2 was mixed in 1% sodium hyaluronate gel (final H 2 O 2 concentration 0.5%) before administration to slow drug release and minimize local discomfort. The mixture was injected intratumorally under ultrasound guidance twice weekly 1 hour before RT. The primary endpoint was patient-reported maximum intratumoral pain intensity before and 24 hours postinjection. Secondary endpoints included grade ≥3 skin toxicity and tumor response by ultrasound. Blood samples were collected before, during, and at the end of treatment for cell-death and immune marker analysis.Results Compliance with H 2 O 2 and RT was 100%. Five of 12 patients reported moderate pain after injection (grade 2 Common Terminology Criteria for Adverse Events v4.02) with median duration 60 minutes (interquartile range, 20-120 minutes). Skin toxicity was comparable to RT alone, with maintained partial/complete tumor response relative to baseline in 11 of 12 patients at last follow-up (median 12 months). Blood marker analysis highlighted significant associations of TRAIL, IL-1β, IL-4, and MIP-1α with tumor response.Conclusions Intratumoral H 2 O 2 with RT is well tolerated with no additional toxicity compared with RT alone. If efficacy is confirmed in a randomized phase 2 trial, the approach has potential as a cost-effective radiation response enhancer in multiple cancer types in which locoregional control after RT alone remains poor..
Coles, C.E.
Haviland, J.S.
Kirby, A.M.
(2020). Internal mammary node irradiation in breast cancer: does benefit outweigh risk?. The lancet. oncology,
Vol.21
(12),
pp. 1541-1543.
Ranger, A.
Dunlop, A.
Shah, P.
Amin, K.
Henderson, D.
Bartlett, F.R.
Knowles, C.
Brigden, B.
Lacey, C.
Donovan, E.
Harris, E.
Kirby, A.M.
(2019). Evaluation of a Novel Field-placement Algorithm for Locoregional Breast Cancer Radiotherapy Including the Internal Mammary Chain. Clinical oncology,
Vol.31
(1),
pp. 25-33.
Bhattacharya, I.S.
Haviland, J.S.
Kirby, A.M.
Kirwan, C.C.
Hopwood, P.
Yarnold, J.R.
Bliss, J.M.
Coles, C.E.
IMPORT Trialists,
(2019). Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial. Journal of clinical oncology : official journal of the american society of clinical oncology,
Vol.37
(4),
pp. 305-317.
show abstract
Purpose IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported outcome measures collected at serial time points are now reported.Patients and methods IMPORT LOW recruited women with low-risk breast cancer after breast-conserving surgery. Patients were randomly assigned to 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast and 40 Gy partial-breast radiotherapy (reduced-dose), or 40 Gy partial-breast radiotherapy only (partial-breast) in 15 fractions. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 and Breast Cancer-Specific Module, Body Image Scale, protocol-specific items, and the Hospital Anxiety and Depression Scale were administered at baseline, 6 months, and 1, 2, and 5 years. Patterns of moderate/marked adverse effects (AEs) were assessed using longitudinal regression models, and baseline predictors were investigated.Results A total of 41 of 71 centers participated in the patient-reported outcome measures substudy; 1,265 (95%) of 1,333 patients consented, and 557 (58%) of 962 reported no moderate/marked AEs at 5 years. Breast appearance change was most prevalent and persisted over time (approximately 20% at each time point). Prevalence of breast hardness, pain, oversensitivity, edema, and skin changes reduced over time ( P < .001 for each), whereas breast shrinkage increased ( P < .001). Analysis by treatment group showed average number of AEs per person was lower in partial-breast (incidence rate ratio, 0.77; 95% CI, 0.71 to 0.84; P < .001) and reduced-dose (incidence rate ratio, 0.83; 95% CI, 0.76 to 0.90; P < .001) versus whole-breast group and decreased over time in all groups. Younger age, larger breast size/surgical deficit, lymph node positivity, and higher levels of anxiety/depression were baseline predictors of subsequent AE reporting.Conclusion Most AEs reduced over time, with fewer AEs in the partial-breast and reduced-dose groups. Baseline predictors for AE reporting were identified. These findings will facilitate informed discussion and shared decision making for future patients receiving moderately hypofractionated breast radiotherapy..
Bhattacharya, I.S.
Haviland, J.S.
Hopwood, P.
Coles, C.E.
Yarnold, J.R.
Bliss, J.M.
Kirby, A.M.
IMPORT Trialists,
(2019). Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiotherapy and oncology : journal of the european society for therapeutic radiology and oncology,
Vol.134,
pp. 220-230.
show abstract
Background In an era of low local relapse rates after adjuvant breast radiotherapy, risks of late normal-tissue effects (NTE) need to be balanced against risk of relapse. NTE are assessed using patient-reported outcome measures (PROMs), clinician-reported outcomes (CRO) and photographs. This analysis investigates whether PROMs can be used as primary NTE endpoints in breast radiotherapy trials.Methods Analyses were conducted within IMPORT LOW (ISRCTN12852634) at 2 and 5 years. NTE were recorded by CRO, photographs and PROMs. Measures of agreement tested concordance, risk ratios for radiotherapy groups were compared, and influence of baseline characteristics on concordance investigated.Results In 1095 patients who consented to PROMS and photographs, PROMs were available at 2 and/or 5 years for 976 patients, of whom 909 had CRO and 844 had photographs. Few patients had moderate/marked NTE, irrespective of method used (eg. 19% patients and 9% clinicians reported breast shrinkage at year-5). Patients reported more NTE than assessed from CRO or photographs (p < 0.001 for most NTE). Concordance between assessments was poor on an individual patient level; eg. for year-5 breast shrinkage, % agreement = 48% and weighted kappa = 0.17. Risk ratios comparing radiotherapy schedules were consistent between PROMs and CRO or photographs.Conclusions Few patients had moderate/marked NTE irrespective of method used. Patients reported more NTE than CRO and photographs, therefore NTE may be underestimated if PROMs are not used. Despite poor concordance between methods, effect sizes from PROMs were consistent with CRO and photographs, suggesting PROMs can be used as primary NTE endpoints in breast radiotherapy trials..
Dunlop, A.
Colgan, R.
Kirby, A.
Ranger, A.
Blasiak-Wal, I.
(2019). Evaluation of organ motion-based robust optimisation for VMAT planning for breast and internal mammary chain radiotherapy. Clinical and translational radiation oncology,
Vol.16,
pp. 60-66.
Bhattacharya, I.S.
Haviland, J.S.
Perotti, C.
Eaton, D.
Gulliford, S.
Harris, E.
Coles, C.E.
Kirwan, C.C.
Bliss, J.M.
Kirby, A.M.
IMPORT Trialists,
(2019). Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trial. Radiotherapy and oncology : journal of the european society for therapeutic radiology and oncology,
Vol.136,
pp. 190-196.
show abstract
Background Seroma describes a collection of serous fluid within a cavity, occurring following surgery. Seroma is associated with normal tissue effects (NTE) following breast radiotherapy, as reported by clinicians and on photographs. This study investigates the association between seroma and the NTE breast appearance change collected using patient-reported outcome measures (PROMs) in IMPORT HIGH, as well as investigating the association between breast appearance change and patient/tumour/treatment factors.Methods Case-control methodology was used for seroma analysis within IMPORT HIGH. Cases were patients reporting moderate/marked breast appearance change and controls reported none/mild changes at year-3. One control was selected at random for each case. Seromas were graded as not visible/subtle or visible/highly visible on CT radiotherapy planning scans. Logistic regression tested associations, adjusting for patient/tumour/treatment factors.Results 1078/1149 patients consented to PROMs, of whom 836 (78%) reported whether they had 3-year breast appearance change; 231 cases and 231 controls were identified. 304/462 (66%) patients received chemotherapy. Seroma prevalence was 20% (41/202) in cases and 16% (32/205) in controls, and less frequent in patients receiving adjuvant chemotherapy [10% (24/246) compared with 29% (40/138) without]. Visible seroma was not significantly associated with breast appearance change [OR 1.38 (95%CI 0.83-2.29), p = 0.219]. Larger tumour size, haematoma, current smoking and body image concerns at baseline were independent risk factors.Conclusions Seroma was not associated with patient-reported breast appearance change, but haematoma and smoking were significant risk factors. Lack of association may be related to lower prevalence of seroma compared with previous reports, perhaps reflecting patients receiving adjuvant chemotherapy in whom seroma resolves prior to radiotherapy..
Kaidar-Person, O.
Vrou Offersen, B.
Hol, S.
Arenas, M.
Aristei, C.
Bourgier, C.
Cardoso, M.J.
Chua, B.
Coles, C.E.
Engberg Damsgaard, T.
Gabrys, D.
Jagsi, R.
Jimenez, R.
Kirby, A.M.
Kirkove, C.
Kirova, Y.
Kouloulias, V.
Marinko, T.
Meattini, I.
Mjaaland, I.
Nader Marta, G.
Witt Nystrom, P.
Senkus, E.
Skyttä, T.
Tvedskov, T.F.
Verhoeven, K.
Poortmans, P.
(2019). ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. Radiotherapy and oncology,
Vol.137,
pp. 159-166.
Bhattacharya, I.S.
Kirby, A.M.
Bliss, J.M.
Coles, C.E.
(2018). Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?. Clinical oncology (royal college of radiologists (great britain)),
Vol.30
(3),
pp. 158-165.
show abstract
Adjuvant radiotherapy after breast-conserving surgery has been an important component of the standard of care for early breast cancer. Improvements in breast cancer care have resulted in a substantial reduction in local relapse rates over recent decades. Although the proportional benefits of adjuvant radiotherapy are similar for different prognostic risk groups of patients, the absolute benefits depend on the risk of relapse and therefore vary considerably between prognostic groups. Radiotherapy is not without risk and for some patients at very low risk of relapse the risks of radiotherapy may outweigh the benefit, leading to potential overtreatment. Randomised controlled trial (RCT) evidence shows that omission of radiotherapy in low risk early breast cancer does not reduce overall survival or increase breast cancer mortality and local recurrences are salvageable. Despite this there has not been a change in practice regarding omission of radiotherapy. The reasons for this may include challenges in patient selection. Recent advances in immunohistochemistry and genomic profiling may improve risk stratification and the development of biomarkers to directed therapies. Several RCTs have quantified the benefit of radiotherapy in reducing local relapse. Where a treatment benefit is known but is considered to be so small not to be clinically relevant then alternatives to RCTs may be considered to answer the question of need. This is because we can assess risk against a fixed 'absolute' boundary rather than needing a randomised comparator. The prospective cohort study is an alternative to the RCT design to answer the question of need for radiotherapy. The feasibility of recruitment into biomarker-directed de-escalation studies will become apparent as more studies open. The challenge is to determine if we are able to accurately risk stratify patients and avoid unnecessary toxicity, thereby tailoring the need for adjuvant breast radiotherapy on an individual patient basis..
Ranger, A.
Dunlop, A.
Hutchinson, K.
Convery, H.
Maclennan, M.K.
Chantler, H.
Twyman, N.
Rose, C.
McQuaid, D.
Amos, R.A.
Griffin, C.
deSouza, N.M.
Donovan, E.
Harris, E.
Coles, C.E.
Kirby, A.
(2018). A Dosimetric Comparison of Breast Radiotherapy Techniques to Treat Locoregional Lymph Nodes Including the Internal Mammary Chain. Clinical oncology (royal college of radiologists (great britain)),
Vol.30
(6),
pp. 346-353.
show abstract
Aims Radiotherapy target volumes in early breast cancer treatment increasingly include the internal mammary chain (IMC). In order to maximise survival benefits of IMC radiotherapy, doses to the heart and lung should be minimised. This dosimetry study compared the ability of three-dimensional conformal radiotherapy, arc therapy and proton beam therapy (PBT) techniques with and without breath-hold to achieve target volume constraints while minimising dose to organs at risk (OARs).Materials and methods In 14 patients' datasets, seven IMC radiotherapy techniques were compared: wide tangent (WT) three-dimensional conformal radiotherapy, volumetric-modulated arc therapy (VMAT) and PBT, each in voluntary deep inspiratory breath-hold (vDIBH) and free breathing (FB), and tomotherapy in FB only. Target volume coverage and OAR doses were measured for each technique. These were compared using a one-way ANOVA with all pairwise comparisons tested using Bonferroni's multiple comparisons test, with adjusted P-values ≤ 0.05 indicating statistical significance.Results One hundred per cent of WT(vDIBH), 43% of WT(FB), 100% of VMAT(vDIBH), 86% of VMAT(FB), 100% of tomotherapy FB and 100% of PBT plans in vDIBH and FB passed all mandatory constraints. However, coverage of the IMC with 90% of the prescribed dose was significantly better than all other techniques using VMAT(vDIBH), PBT(vDIBH) and PBT(FB) (mean IMC coverage ± 1 standard deviation = 96.0% ± 4.3, 99.8% ± 0.3 and 99.0% ± 0.2, respectively). The mean heart dose was significantly reduced in vDIBH compared with FB for both the WT (P < 0.0001) and VMAT (P < 0.0001) techniques. There was no advantage in target volume coverage or OAR doses for PBT(vDIBH) compared with PBT(FB).Conclusions Simple WT radiotherapy delivered in vDIBH achieves satisfactory coverage of the IMC while meeting heart and lung dose constraints. However, where higher isodose coverage is required, VMAT(vDIBH) is the optimal photon technique. The lowest OAR doses are achieved by PBT, in which the use of vDIBH does not improve dose statistics..
O'Connell, R.L.
Di Micco, R.
Khabra, K.
Kirby, A.M.
Harris, P.A.
James, S.E.
Power, K.
Ramsey, K.W.
Rusby, J.E.
(2018). Comparison of Immediate versus Delayed DIEP Flap Reconstruction in Women Who Require Postmastectomy Radiotherapy. Plastic and reconstructive surgery,
Vol.142
(3),
pp. 594-605.
show abstract
Background The authors investigated aesthetic outcome and patient satisfaction in women who have undergone deep inferior epigastric artery perforator (DIEP) flap reconstruction in the setting of postmastectomy radiotherapy. Patients who underwent DIEP flap reconstruction without postmastectomy radiotherapy were the control group.Methods Participants who had undergone DIEP flap reconstruction between September 1, 2009, and September 1, 2014, were recruited, answered the BREAST-Q, and underwent three-dimensional surface-imaging. A panel assessed the aesthetic outcome by reviewing these images.Results One hundred sixty-seven women participated. Eighty women (48 percent) underwent immediate DIEP flap reconstruction and no postmastectomy radiotherapy; 28 (17 percent) underwent immediate DIEP flap reconstruction with postmastectomy radiotherapy; 38 (23 percent) underwent simple mastectomy, postmastectomy radiotherapy, and DIEP flap reconstruction; and 21 (13 percent) underwent mastectomy with temporizing implant, postmastectomy radiotherapy, and DIEP flap reconstruction. Median satisfaction scores were significantly different among the groups (p < 0.05). Post hoc comparison demonstrated that women who had an immediate DIEP flap reconstruction were significantly less satisfied if they had postmastectomy radiotherapy. In women requiring radiotherapy, those undergoing delayed reconstruction after a simple mastectomy were most satisfied, but there was no significant difference between the immediate DIEP flap and temporizing implant groups. Median panel scores differed among groups, being significantly higher if the immediate reconstruction was not subjected to radiotherapy. There was no significant difference in panel assessment among the three groups of women who had received radiotherapy.Conclusions Patients who avoid having their immediate DIEP flap reconstruction irradiated are more satisfied and have better aesthetic outcome than those who undergo postmastectomy radiotherapy. In women requiring radiotherapy and who wish to have an immediate or "delayed-immediate" reconstruction, there were no significant differences in panel or patient satisfaction. Therefore, immediate DIEP flap reconstruction or mastectomy with temporizing implant then DIEP flap surgery are acceptable treatment pathways in the context of post-mastectomy radiotherapy..
O'Leary, B.
Alarcon, L.
Mallon, E.
Kirby, A.
(2017). Radiotherapy-associated Pemphigus - a Rare Cause of Grade 4 Skin Toxicity. Clinical oncology (royal college of radiologists (great britain)),
Vol.29
(1),
pp. e50-?.
Mitchell, R.A.
Wai, P.
Colgan, R.
Kirby, A.M.
Donovan, E.M.
(2017). Improving the efficiency of breast radiotherapy treatment planning using a semi-automated approach. Journal of applied clinical medical physics,
Vol.18
(1),
pp. 18-24.
show abstract
Objectives To reduce treatment planning times while maintaining plan quality through the introduction of semi-automated planning techniques for breast radiotherapy.Methods Automatic critical structure delineation was examined using the Smart Probabilistic Image Contouring Engine (SPICE) commercial autosegmentation software (Philips Radiation Oncology Systems, Fitchburg, WI) for a cohort of ten patients. Semiautomated planning was investigated by employing scripting in the treatment planning system to automate segment creation for breast step-and-shoot planning and create objectives for segment weight optimization; considerations were made for three different multileaf collimator (MLC) configurations. Forty patients were retrospectively planned using the script and a planning time comparison performed.Results The SPICE heart and lung outlines agreed closely with clinician-defined outlines (median Dice Similarity Coefficient > 0.9); median difference in mean heart dose was 0.0 cGy (range -10.8 to 5.4 cGy). Scripted treatment plans demonstrated equivalence with their clinical counterparts. No statistically significant differences were found for target parameters. Minimal ipsilateral lung dose increases were also observed. Statistically significant (P < 0.01) time reductions were achievable for MLCi and Agility MLC (Elekta Ltd, Crawley, UK) plans (median 4.9 and 5.9 min, respectively).Conclusions The use of commercial autosegmentation software enables breast plan adjustment based on doses to organs at risk. Semi-automated techniques for breast radiotherapy planning offer modest reductions in planning times. However, in the context of a typical department's breast radiotherapy workload, minor savings per plan translate into greater efficiencies overall..
Bartlett, F.R.
Donovan, E.M.
McNair, H.A.
Corsini, L.A.
Colgan, R.M.
Evans, P.M.
Maynard, L.
Griffin, C.
Haviland, J.S.
Yarnold, J.R.
Kirby, A.M.
(2017). The UK HeartSpare Study (Stage II): Multicentre Evaluation of a Voluntary Breath-hold Technique in Patients Receiving Breast Radiotherapy. Clinical oncology (royal college of radiologists (great britain)),
Vol.29
(3),
pp. e51-e56.
show abstract
Aims To evaluate the feasibility and heart-sparing ability of the voluntary breath-hold (VBH) technique in a multicentre setting.Materials and methods Patients were recruited from 10 UK centres. Following surgery for early left breast cancer, patients with any heart inside the 50% isodose from a standard free-breathing tangential field treatment plan underwent a second planning computed tomography (CT) scan using the VBH technique. A separate treatment plan was prepared on the VBH CT scan and used for treatment. The mean heart, left anterior descending coronary artery (LAD) and lung doses were calculated. Daily electronic portal imaging (EPI) was carried out and scanning/treatment times were recorded. The primary end point was the percentage of patients achieving a reduction in mean heart dose with VBH. Population systematic (Σ) and random errors (σ) were estimated. Within-patient comparisons between techniques used Wilcoxon signed-rank tests.Results In total, 101 patients were recruited during 2014. Primary end point data were available for 93 patients, 88 (95%) of whom achieved a reduction in mean heart dose with VBH. Mean cardiac doses (Gy) for free-breathing and VBH techniques, respectively, were: heart 1.8 and 1.1, LAD 12.1 and 5.4, maximum LAD 35.4 and 24.1 (all P<0.001). Population EPI-based displacement data showed Σ =+1.3-1.9 mm and σ=1.4-1.8 mm. Median CT and treatment session times were 21 and 22 min, respectively.Conclusions The VBH technique is confirmed as effective in sparing heart tissue and is feasible in a multicentre setting..
Mehta, S.
Kirby, A.
(2017). Audit of local practice regarding interval between surgery and adjuvant radiotherapy in patients with early breast cancer. Clinical oncology,
Vol.29,
pp. S2-S2.
O'Connell, R.L.
Di Micco, R.
Khabra, K.
Wolf, L.
deSouza, N.
Roche, N.
Barry, P.A.
Kirby, A.M.
Rusby, J.E.
(2017). The potential role of three-dimensional surface imaging as a tool to evaluate aesthetic outcome after Breast Conserving Therapy (BCT). Breast cancer research and treatment,
Vol.164
(2),
pp. 385-393.
show abstract
Purpose To establish whether objective measurements of symmetry of volume and shape using three-dimensional surface imaging (3D-SI) can be used as surrogate markers of aesthetic outcome in patients who have undergone breast conserving therapy (BCT).Methods Women who had undergone unilateral BCT in the preceding 1-6 years were invited to participate. Participants completed a satisfaction questionnaire (BREAST-Q) and underwent 3D-SI. Volume and surface symmetry were measured on the images. Assessment of aesthetic outcome was undertaken by a panel of clinicians. The Kruskal-Wallis test was used to assess the relationship between volume and shape symmetry measurements with the panel score. Spearman's rho correlations were used to assess the relationship between the measurements and patient satisfaction.Results 200 women participated. Median volume symmetry was 87% (IQR 78-93) and shape symmetry was 5.9 mm (IQR 4.2-8.0). The participants were grouped according to panel assessment of aesthetic outcome (poor, fair, good, excellent) and the median volume and shape symmetry was calculated for each group. Volume symmetry significantly differed between the groups. Post hoc pairwise comparisons demonstrated that these differences existed between panel scores of fair versus good and good versus excellent. Median shape symmetry also differed according to patient panel groups with four significant pairwise comparisons between poor versus good, poor versus excellent, fair versus good and fair versus excellent. There was a significant but weak correlation of both volume symmetry and surface asymmetry with BREAST-Q scores (correlation coefficients 0.187 and -0.229, respectively).Conclusion Breast volume and shape symmetry are both associated with panel assessment scores and patient satisfaction. The objective volume and shape symmetry measures were strongly associated with panel assessment scores, such that a 3D-SI tool could replace panel assessment as a faster and more objective method of evaluating aesthetic outcomes..
O'Connell, R.L.
Di Micco, R.
Khabra, K.
Wolf, L.
deSouza, N.
Roche, N.
Barry, P.A.
Kirby, A.M.
Rusby, J.E.
(2017). The potential role of three-dimensional surface imaging as a tool to evaluate aesthetic outcome after Breast Conserving Therapy (BCT). Breast cancer research and treatment,
Vol.164
(2),
pp. 385-393.
Coles, C.E.
Griffin, C.L.
Kirby, A.M.
Titley, J.
Agrawal, R.K.
Alhasso, A.
Bhattacharya, I.S.
Brunt, A.M.
Ciurlionis, L.
Chan, C.
Donovan, E.M.
Emson, M.A.
Harnett, A.N.
Haviland, J.S.
Hopwood, P.
Jefford, M.L.
Kaggwa, R.
Sawyer, E.J.
Syndikus, I.
Tsang, Y.M.
Wheatley, D.A.
Wilcox, M.
Yarnold, J.R.
Bliss, J.M.
IMPORT Trialists,
(2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet (london, england),
Vol.390
(10099),
pp. 1048-1060.
show abstract
Background Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy restricted to the vicinity of the original tumour in women at lower than average risk of local relapse will improve the balance of beneficial versus adverse effects compared with whole-breast radiotherapy.Methods IMPORT LOW is a multicentre, randomised, controlled, phase 3, non-inferiority trial done in 30 radiotherapy centres in the UK. Women aged 50 years or older who had undergone breast-conserving surgery for unifocal invasive ductal adenocarcinoma of grade 1-3, with a tumour size of 3 cm or less (pT1-2), none to three positive axillary nodes (pN0-1), and minimum microscopic margins of non-cancerous tissue of 2 mm or more, were recruited. Patients were randomly assigned (1:1:1) to receive 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast radiotherapy and 40 Gy to the partial breast (reduced-dose group), or 40 Gy to the partial breast only (partial-breast group) in 15 daily treatment fractions. Computer-generated random permuted blocks (mixed sizes of six and nine) were used to assign patients to groups, stratifying patients by radiotherapy treatment centre. Patients and clinicians were not masked to treatment allocation. Field-in-field intensity-modulated radiotherapy was delivered using standard tangential beams that were simply reduced in length for the partial-breast group. The primary endpoint was ipsilateral local relapse (80% power to exclude a 2·5% increase [non-inferiority margin] at 5 years for each experimental group; non-inferiority was shown if the upper limit of the two-sided 95% CI for the local relapse hazard ratio [HR] was less than 2·03), analysed by intention to treat. Safety analyses were done in all patients for whom data was available (ie, a modified intention-to-treat population). This study is registered in the ISRCTN registry, number ISRCTN12852634.Findings Between May 3, 2007, and Oct 5, 2010, 2018 women were recruited. Two women withdrew consent for use of their data in the analysis. 674 patients were analysed in the whole-breast radiotherapy (control) group, 673 in the reduced-dose group, and 669 in the partial-breast group. Median follow-up was 72·2 months (IQR 61·7-83·2), and 5-year estimates of local relapse cumulative incidence were 1·1% (95% CI 0·5-2·3) of patients in the control group, 0·2% (0·02-1·2) in the reduced-dose group, and 0·5% (0·2-1·4) in the partial-breast group. Estimated 5-year absolute differences in local relapse compared with the control group were -0·73% (-0·99 to 0·22) for the reduced-dose and -0·38% (-0·84 to 0·90) for the partial-breast groups. Non-inferiority can be claimed for both reduced-dose and partial-breast radiotherapy, and was confirmed by the test against the critical HR being more than 2·03 (p=0·003 for the reduced-dose group and p=0·016 for the partial-breast group, compared with the whole-breast radiotherapy group). Photographic, patient, and clinical assessments recorded similar adverse effects after reduced-dose or partial-breast radiotherapy, including two patient domains achieving statistically significantly lower adverse effects (change in breast appearance [p=0·007 for partial-breast] and breast harder or firmer [p=0·002 for reduced-dose and p<0·0001 for partial-breast]) compared with whole-breast radiotherapy.Interpretation We showed non-inferiority of partial-breast and reduced-dose radiotherapy compared with the standard whole-breast radiotherapy in terms of local relapse in a cohort of patients with early breast cancer, and equivalent or fewer late normal-tissue adverse effects were seen. This simple radiotherapy technique is implementable in radiotherapy centres worldwide.Funding Cancer Research UK..
Harris, E.J.
Mukesh, M.B.
Donovan, E.M.
Kirby, A.M.
Haviland, J.S.
Jena, R.
Yarnold, J.
Baker, A.
Dean, J.
Eagle, S.
Mayles, H.
Griffin, C.
Perry, R.
Poynter, A.
Coles, C.E.
Evans, P.M.
IMPORT high trialists,
(2016). A multicentre study of the evidence for customized margins in photon breast boost radiotherapy. The british journal of radiology,
Vol.89
(1058),
pp. 20150603-?.
show abstract
Objective To determine if subsets of patients may benefit from smaller or larger margins when using laser setup and bony anatomy verification of breast tumour bed (TB) boost radiotherapy (RT).Methods Verification imaging data acquired using cone-beam CT, megavoltage CT or two-dimensional kilovoltage imaging on 218 patients were used (1574 images). TB setup errors for laser-only setup (dlaser) and for bony anatomy verification (dbone) were determined using clips implanted into the TB as a gold standard for the TB position. Cases were grouped by centre-, patient- and treatment-related factors, including breast volume, TB position, seroma visibility and surgical technique. Systematic (Σ) and random (σ) TB setup errors were compared between groups, and TB planning target volume margins (MTB) were calculated.Results For the study population, Σlaser was between 2.8 and 3.4 mm, and Σbone was between 2.2 and 2.6 mm, respectively. Females with larger breasts (p = 0.03), easily visible seroma (p ≤ 0.02) and open surgical technique (p ≤ 0.04) had larger Σlaser. Σbone was larger for females with larger breasts (p = 0.02) and lateral tumours (p = 0.04). Females with medial tumours (p < 0.01) had smaller Σbone.Conclusion If clips are not used, margins should be 8 and 10 mm for bony anatomy verification and laser setup, respectively. Individualization of TB margins may be considered based on breast volume, TB and seroma visibility.Advances in knowledge Setup accuracy using lasers and bony anatomy is influenced by patient and treatment factors. Some patients may benefit from clip-based image guidance more than others..
O'Connell, R.L.
DiMicco, R.
Khabra, K.
O'Flynn, E.A.
deSouza, N.
Roche, N.
Barry, P.A.
Kirby, A.M.
Rusby, J.E.
(2016). Initial experience of the BREAST-Q breast-conserving therapy module. Breast cancer research and treatment,
Vol.160
(1),
pp. 79-89.
show abstract
Purpose The most recently developed module of the BREAST-Q, a validated patient outcome measure, is for patients who have undergone breast-conserving therapy (BCT) for cancer. This aim of this study was to assess patient satisfaction and quality of life after BCT using BREAST-Q, investigate clinical risk factors for lower satisfaction and explore the relationship between patient satisfaction with the appearance of their breasts and the other domains of the BREAST-Q.Methods Women who had undergone unilateral BCT in the preceding 1-6 years were invited to participate at the time of their annual surveillance mammogram. Clinicopathological data were collected from an electronic database. Linear regression was used to evaluate risk factors for lower satisfaction. Spearman's rho correlation coefficients were calculated to evaluate the relationship between domains.Results 200 women completed the questionnaire. Mean age was 60 years (SD 11.1). Time from surgery was 35.5 months (SD 17.8). Median score for 'Satisfaction with breasts' was 68 (interquartile range 55-80). Lowest scores were for 'sexual wellbeing' (57, IQR 45-66). On multivariate analysis, BMI at the time of surgery (p = 0.002), delayed wound healing (p = 0.001) and axillary surgery (p = 0.003) were independent risk factors for lower satisfaction. There was significant correlation between 'Satisfaction with breasts' and all other BREAST-Q domains.Conclusion High BMI, delayed wound healing and axillary surgery are risk factors for lower patient satisfaction. This first publication reporting the whole dataset for the BREAST-Q BCT will serve as a benchmark for future studies of patient satisfaction following BCT..
Dunkerley, N.
Bartlett, F.R.
Kirby, A.M.
Evans, P.M.
Donovan, E.M.
(2016). Mean heart dose variation over a course of breath-holding breast cancer radiotherapy. The british journal of radiology,
Vol.89
(1067),
pp. 20160536-?.
show abstract
Objective The purpose of the work was to estimate the dose received by the heart throughout a course of breath-holding breast radiotherapy.Methods 113 cone-beam CT (CBCT) scans were acquired for 20 patients treated within the HeartSpare 1A study, in which both an active breathing control (ABC) device and a voluntary breath-hold (VBH) method were used. Predicted mean heart doses were obtained from treatment plans. CBCT scans were imported into a treatment planning system, heart outlines defined, images registered to the CT planning scan and mean heart dose recorded. Two observers outlined two cases three times each to assess interobserver and intraobserver variation.Results There were no statistically significant differences between ABC and VBH heart dose data from CT planning scans, or in the CBCT-based estimates of heart dose, and no effect from the order of the breath-hold method. Variation in mean heart dose per fraction over the three imaged fractions was <6 cGy without setup correction, decreasing to 3.3 cGy with setup correction. If scaled to 15 fractions, all differences between predicted and estimated mean heart doses were <0.5 Gy and in 80% of cases, they were <0.25 Gy.Conclusion Variation in mean heart dose was at an acceptable level over the duration of breath-holding radiotherapy and was well predicted by the planning system. Advances in knowledge: Mean heart dose was not adversely affected by fraction-to-fraction variations throughout a course of heart-sparing radiotherapy using two well-established breath-holding methods..
Landeg, S.J.
Kirby, A.M.
Lee, S.F.
Bartlett, F.
Titmarsh, K.
Donovan, E.
Griffin, C.L.
Gothard, L.
Locke, I.
McNair, H.A.
(2016). A randomized control trial evaluating fluorescent ink versus dark ink tattoos for breast radiotherapy. The british journal of radiology,
Vol.89
(1068),
pp. 20160288-?.
show abstract
Objective The purpose of this UK study was to evaluate interfraction reproducibility and body image score when using ultraviolet (UV) tattoos (not visible in ambient lighting) for external references during breast/chest wall radiotherapy and compare with conventional dark ink.Methods In this non-blinded, single-centre, parallel group, randomized control trial, patients were allocated to receive either conventional dark ink or UV ink tattoos using computer-generated random blocks. Participant assignment was not masked. Systematic (∑) and random (σ) setup errors were determined using electronic portal images. Body image questionnaires were completed at pre-treatment, 1 month and 6 months to determine the impact of tattoo type on body image. The primary end point was to determine that UV tattoo random error (σ setup ) was no less accurate than with conventional dark ink tattoos, i.e. <2.8 mm.Results 46 patients were randomized to receive conventional dark or UV ink tattoos. 45 patients completed treatment (UV: n = 23, dark: n = 22). σ setup for the UV tattoo group was <2.8 mm in the u and v directions (p = 0.001 and p = 0.009, respectively). A larger proportion of patients reported improvement in body image score in the UV tattoo group compared with the dark ink group at 1 month [56% (13/23) vs 14% (3/22), respectively] and 6 months [52% (11/21) vs 38% (8/21), respectively].Conclusion UV tattoos were associated with interfraction setup reproducibility comparable with conventional dark ink. Patients reported a more favourable change in body image score up to 6 months following treatment. Advances in knowledge: This study is the first to evaluate UV tattoo external references in a randomized control trial..
Bartlett, F.R.
Colgan, R.M.
Donovan, E.M.
McNair, H.A.
Carr, K.
Evans, P.M.
Griffin, C.
Locke, I.
Haviland, J.S.
Yarnold, J.R.
Kirby, A.M.
(2015). The UK HeartSpare Study (Stage IB): Randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. Radiotherapy and oncology,
Vol.114
(1),
pp. 66-72.
Hanna, G.G.
Kirby, A.M.
(2015). Intraoperative radiotherapy in early stage breast cancer: potential indications and evidence to date. The british journal of radiology,
Vol.88
(1049),
pp. 20140686-20140686.
Kirby, A.
Hanna, G.
Wilcox, M.
MacKenzie, M.
(2015). In Regard to Vaidya et al. International journal of radiation oncology*biology*physics,
Vol.92
(5),
pp. 957-958.
Colgan, R.
James, M.
Bartlett, F.R.
Kirby, A.M.
Donovan, E.M.
(2015). Voluntary breath-holding for breast cancer radiotherapy is consistent and stable. The british journal of radiology,
Vol.88
(1054),
pp. 20150309-20150309.
Taylor, C.W.
Kirby, A.M.
(2015). Cardiac Side-effects From Breast Cancer Radiotherapy. Clinical oncology,
Vol.27
(11),
pp. 621-629.
Tsang, Y.
Ciurlionis, L.
Kirby, A.M.
Locke, I.
Venables, K.
Yarnold, J.R.
Titley, J.
Bliss, J.
Coles, C.E.
(2015). Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom. The british journal of radiology,
Vol.88
(1056),
pp. 20150453-20150453.
Harris, E.J.
Mukesh, M.
Jena, R.
Baker, A.
Bartelink, H.
Brooks, C.
Dean, J.
Donovan, E.M.
Collette, S.
Eagle, S.
Fenwick, J.D.
Graham, P.H.
Haviland, J.S.
Kirby, A.M.
Mayles, H.
Mitchell, R.A.
Perry, R.
Poortmans, P.
Poynter, A.
Shentall, G.
Titley, J.
Thompson, A.
Yarnold, J.R.
Coles, C.E.
Evans, P.M.
(2014). A multicentre observational study evaluating image-guided radiotherapy for more accurate partial-breast intensity-modulated radiotherapy: comparison with standard imaging technique. Efficacy and mechanism evaluation,
Vol.1
(3).
Bartlett, F.R.
Yarnold, J.R.
Kirby, A.M.
(2014). Response to D Woolf and M Keshtgar's reply to: breast radiotherapy and heart disease - where are we now?. Clin oncol (r coll radiol),
Vol.26
(2),
p. 123.
Bartlett, F.R.
Colgan, R.M.
Donovan, E.M.
Carr, K.
Landeg, S.
Clements, N.
McNair, H.A.
Locke, I.
Evans, P.M.
Haviland, J.S.
Yarnold, J.R.
Kirby, A.M.
(2014). Voluntary breath-hold technique for reducing heart dose in left breast radiotherapy. J vis exp,
(89).
show abstract
Breath-holding techniques reduce the amount of radiation received by cardiac structures during tangential-field left breast radiotherapy. With these techniques, patients hold their breath while radiotherapy is delivered, pushing the heart down and away from the radiotherapy field. Despite clear dosimetric benefits, these techniques are not yet in widespread use. One reason for this is that commercially available solutions require specialist equipment, necessitating not only significant capital investment, but often also incurring ongoing costs such as a need for daily disposable mouthpieces. The voluntary breath-hold technique described here does not require any additional specialist equipment. All breath-holding techniques require a surrogate to monitor breath-hold consistency and whether breath-hold is maintained. Voluntary breath-hold uses the distance moved by the anterior and lateral reference marks (tattoos) away from the treatment room lasers in breath-hold to monitor consistency at CT-planning and treatment setup. Light fields are then used to monitor breath-hold consistency prior to and during radiotherapy delivery. .
Phillips, I.
Locke, I.
Kirby, A.
Rahman, F.
(2014). Palliative External Beam Radiotherapy for Painful Bone Metastases. Clinical oncology,
Vol.26,
pp. S1-+.
Kirby, A.N.
Jena, R.
Harris, E.J.
Evans, P.M.
Crowley, C.
Gregory, D.L.
Coles, C.E.
(2013). Tumour bed delineation for partial breast/breast boost radiotherapy: what is the optimal number of implanted markers?. Radiother oncol,
Vol.106
(2),
pp. 231-235.
show abstract
PURPOSE: International consensus has not been reached regarding the optimal number of implanted tumour bed (TB) markers for partial breast/breast boost radiotherapy target volume delineation. Four common methods are: insertion of 6 clips (4 radial, 1 deep and 1 superficial), 5 clips (4 radial and 1 deep), 1 clip at the chest wall, and no clips. We compared TB volumes delineated using 6, 5, 1 and 0 clips in women who have undergone wide-local excision (WLE) of breast cancer (BC) with full-thickness closure of the excision cavity, in order to determine the additional margin required for breast boost or partial breast irradiation (PBI) when fewer than 6 clips are used. METHODS: Ten patients with invasive ductal BC who had undergone WLE followed by implantation of six fiducial markers (titanium clips) each underwent CT imaging for radiotherapy planning purposes. Retrospective processing of the DICOM image datasets was performed to remove markers and associated imaging artefacts, using an in-house software algorithm. Four observers outlined TB volumes on four different datasets for each case: (1) all markers present (CT6M); (2) the superficial marker removed (CT(5M)); (3) all but the chest wall marker removed (CTCW); (4) all markers removed (CT(0M)). For each observer, the additional margin required around each of TB(0M), TBCW, and TB(5M) in order to encompass TB(6M) was calculated. The conformity level index (CLI) and differences in centre-of-mass (COM) between observers were quantified for CT(0M), CTCW, CT(5M), CT(6M). RESULTS: The overall median additional margins required to encompass TB(6M) were 8mm (range 0-28 mm) for TB(0M), 5mm (range 1-13 mm) for TBCW, and 2mm (range 0-7 mm) for TB(5M). CLI were higher for TB volumes delineated using CT(6M) (0.31) CT(5M) (0.32) than for CTCW (0.19) and CT(0M) (0.15). CONCLUSIONS: In women who have undergone WLE of breast cancer with full-thickness closure of the excision cavity and who are proceeding to PBI or breast boost RT, target volume delineation based on 0 or 1 implanted markers is not recommended as large additional margins are required to account for uncertainty over true TB location. Five implanted markers (one deep and four radial) are likely to be adequate assuming the addition of a standard 10-15 mm TB-CTV margin. Low CLI values for all TB volumes reflect the sensitivity of low volumes to small differences in delineation and are unlikely to be clinically significant for TB(5M) and TB(6M) in the context of adequate TB-CTV margins..
Bartlett, F.R.
Colgan, R.M.
Carr, K.
Donovan, E.M.
McNair, H.A.
Locke, I.
Evans, P.M.
Haviland, J.S.
Yarnold, J.R.
Kirby, A.M.
(2013). The UK HeartSpare Study: randomised evaluation of voluntary deep-inspiratory breath-hold in women undergoing breast radiotherapy. Radiother oncol,
Vol.108
(2),
pp. 242-247.
show abstract
PURPOSE: To determine whether voluntary deep-inspiratory breath-hold (v_DIBH) and deep-inspiratory breath-hold with the active breathing coordinator™ (ABC_DIBH) in patients undergoing left breast radiotherapy are comparable in terms of normal-tissue sparing, positional reproducibility and feasibility of delivery. METHODS: Following surgery for early breast cancer, patients underwent planning-CT scans in v_DIBH and ABC_DIBH. Patients were randomised to receive one technique for fractions 1-7 and the second technique for fractions 8-15 (40 Gy/15 fractions total). Daily electronic portal imaging (EPI) was performed and matched to digitally-reconstructed radiographs. Cone-beam CT (CBCT) images were acquired for 6/15 fractions and matched to planning-CT data. Population systematic (Σ) and random errors (σ) were estimated. Heart, left-anterior-descending coronary artery, and lung doses were calculated. Patient comfort, radiographer satisfaction and scanning/treatment times were recorded. Within-patient comparisons between the two techniques used the paired t-test or Wilcoxon signed-rank test. RESULTS: Twenty-three patients were recruited. All completed treatment with both techniques. EPI-derived Σ were ≤ 1.8mm (v_DIBH) and ≤ 2.0mm (ABC_DIBH) and σ ≤ 2.5mm (v_DIBH) and ≤ 2.2mm (ABC_DIBH) (all p non-significant). CBCT-derived Σ were ≤ 3.9 mm (v_DIBH) and ≤ 4.9 mm (ABC_DIBH) and σ ≤ 4.1mm (v_DIBH) and ≤ 3.8mm (ABC_DIBH). There was no significant difference between techniques in terms of normal-tissue doses (all p non-significant). Patients and radiographers preferred v_DIBH (p=0.007, p=0.03, respectively). Scanning/treatment setup times were shorter for v_DIBH (p=0.02, p=0.04, respectively). CONCLUSIONS: v_DIBH and ABC_DIBH are comparable in terms of positional reproducibility and normal tissue sparing. v_DIBH is preferred by patients and radiographers, takes less time to deliver, and is cheaper than ABC_DIBH..
Bartlett, F.R.
Yarnold, J.R.
Kirby, A.M.
(2013). Breast radiotherapy and heart disease - where are we now?. Clin oncol (r coll radiol),
Vol.25
(12),
pp. 687-689.
Bartlett, F.R.
Yarnold, J.R.
Donovan, E.M.
Evans, P.M.
Locke, I.
Kirby, A.M.
(2013). Multileaf collimation cardiac shielding in breast radiotherapy: Cardiac doses are reduced, but at what cost?. Clin oncol (r coll radiol),
Vol.25
(12),
pp. 690-696.
show abstract
AIMS: To measure cardiac tissue doses in left-sided breast cancer patients receiving supine tangential field radiotherapy with multileaf collimation (MLC) cardiac shielding of the heart and to assess the effect on target volume coverage. MATERIALS AND METHODS: Sixty-seven consecutive patients who underwent adjuvant radiotherapy to the left breast (n = 48) or chest wall (n = 19) in 2009/2010 were analysed. The heart, left anterior descending coronary artery (LAD), whole breast and partial breast clinical target volumes (WBCTV and PBCTV) were outlined retrospectively (the latter only in patients who had undergone breast-conserving surgery [BCS]). The mean heart and LAD NTDmean and maximum LAD doses (LADmax) were calculated for all patients (NTDmean is a biologically weighted mean dose normalised to 2 Gy fractions using a standard linear quadratic model). Coverage of WBCTV and PBCTV by the 95% isodose was assessed (BCS patients only). RESULTS: The mean heart NTDmean (standard deviation) was 0.8 (0.3) Gy, the mean LAD NTDmean 6.7 (4.3) Gy and the mean LADmax 40.3 (10.1) Gy. Coverage of the WBCTV by 95% isodose was <90% in one in three patients and PBCTV coverage <95% (range 78-94%) in one in 10 BCS patients. CONCLUSION: The use of MLC cardiac shielding reduces doses to cardiac tissues at the expense of target tissue coverage. Formal target volume delineation in combination with an assessment of the likelihood of local relapse is recommended in order to aid decisions regarding field and MLC placement..
Juneja, P.
Harris, E.J.
Kirby, A.M.
Evans, P.M.
(2012). Adaptive breast radiation therapy using modeling of tissue mechanics: a breast tissue segmentation study. Int j radiat oncol biol phys,
Vol.84
(3),
pp. e419-e425.
show abstract
PURPOSE: To validate and compare the accuracy of breast tissue segmentation methods applied to computed tomography (CT) scans used for radiation therapy planning and to study the effect of tissue distribution on the segmentation accuracy for the purpose of developing models for use in adaptive breast radiation therapy. METHODS AND MATERIALS: Twenty-four patients receiving postlumpectomy radiation therapy for breast cancer underwent CT imaging in prone and supine positions. The whole-breast clinical target volume was outlined. Clinical target volumes were segmented into fibroglandular and fatty tissue using the following algorithms: physical density thresholding; interactive thresholding; fuzzy c-means with 3 classes (FCM3) and 4 classes (FCM4); and k-means. The segmentation algorithms were evaluated in 2 stages: first, an approach based on the assumption that the breast composition should be the same in both prone and supine position; and second, comparison of segmentation with tissue outlines from 3 experts using the Dice similarity coefficient (DSC). Breast datasets were grouped into nonsparse and sparse fibroglandular tissue distributions according to expert assessment and used to assess the accuracy of the segmentation methods and the agreement between experts. RESULTS: Prone and supine breast composition analysis showed differences between the methods. Validation against expert outlines found significant differences (P<.001) between FCM3 and FCM4. Fuzzy c-means with 3 classes generated segmentation results (mean DSC = 0.70) closest to the experts' outlines. There was good agreement (mean DSC = 0.85) among experts for breast tissue outlining. Segmentation accuracy and expert agreement was significantly higher (P<.005) in the nonsparse group than in the sparse group. CONCLUSIONS: The FCM3 gave the most accurate segmentation of breast tissues on CT data and could therefore be used in adaptive radiation therapy-based on tissue modeling. Breast tissue segmentation methods should be used with caution in patients with sparse fibroglandular tissue distribution..
Yates, L.
Kirby, A.
Crichton, S.
Gillett, C.
Cane, P.
Fentiman, I.
Sawyer, E.
(2012). RISK FACTORS FOR REGIONAL NODAL RELAPSE IN BREAST CANCER PATIENTS WITH ONE TO THREE POSITIVE AXILLARY NODES. International journal of radiation oncology biology physics,
Vol.82
(5),
pp. 2093-2103.
Kirby, A.M.
Evans, P.M.
Helyer, S.J.
Donovan, E.M.
Convery, H.M.
Yarnold, J.R.
(2011). A randomised trial of supine versus prone breast radiotherapy (SuPr study): comparing set-up errors and respiratory motion. Radiother oncol,
Vol.100
(2),
pp. 221-226.
show abstract
PURPOSE: To test a prone position against the international-standard supine position in women undergoing whole-breast-radiotherapy (WBRT) after wide-local-excision (WLE) of early breast cancer (BC) in terms of feasibility, set-up errors, and respiratory motion. METHODS: Following WLE of BC with insertion of tumour-bed clips, patients underwent 4D-CT for WBRT-planning in supine and prone positions (the latter using an in-house-designed platform). Patients were randomised to undergo WBRT fractions 1-7 in one position, switching to the alternate position for fractions 8-15 (40Gy/15-fractions total). Cone-beam CT-images (CBCT) were acquired prior to fractions 1, 4, 7, 8, 11 and 14. CBCT data were matched to planning-CT data using (i) chest-wall and (ii) clips. Systematic and random errors were calculated. Maximal displacement of chest-wall and clips with respiration was measured on 4D-CT. Clinical- to planning-target-volume (CTV-PTV) margins were calculated. Patient-comfort-scores and treatment-times were evaluated. RESULTS: Twenty-five patients were randomized. 192/192 (100%) planned supine fractions and 173/192 (90%) prone fractions were completed. 3D population systematic errors were 1.3-1.9mm (supine) and 3.1-4.3mm (prone) (p=0.02) and random errors 2.6-3.2mm (supine) and 3.8-5.4mm (prone) (p=0.02). Prone positioning reduced chest-wall and clip motion (0.5±0.2mm (prone) versus 2.7±0.5mm (supine) (p<0.001)) with respiration. Calculated CTV-PTV margins were greater for prone (12-16mm) than for supine treatment (10mm). Patient-comfort-scores and treatment times were comparable (p=0.06). CONCLUSIONS: Set-up errors were greater using our prone technique than for our standard supine technique, resulting in the need for larger CTV-PTV margins in the prone position. Further work is required to optimize the prone treatment-platform and technique before it can become a standard treatment option at our institution..
Barton, S.R.
Smith, I.E.
Kirby, A.M.
Ashley, S.
Walsh, G.
Parton, M.
(2011). The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur j cancer,
Vol.47
(14),
pp. 2099-2106.
show abstract
AIM: To assess the role of ipsilateral breast radiotherapy (IBR) in women with occult primary breast cancer presenting with axillary metastases (OPBC). METHODS: Patients with axillary nodal metastases and histological diagnosis of breast cancer without palpable, mammographic or ultrasonographic evidence of a breast primary were identified from a prospectively maintained single institution database. Imaging, surgery, radiotherapy, recurrence and survival data were collected. Patients whose breast cancer primary was detected on MRI (but occult on clinical examination and other imaging) were excluded from the analyses of IBR and outcome, but were included in other exploratory analyses. RESULTS: Fifty-five patients were included between 1975 and 2009. Median follow up was 68 months. Twenty patients had breast magnetic resonance imaging (MRI) in addition to other imaging. A primary breast cancer was detected in 7 of these 20. 48/55 patients had no detectable breast primary. 35/48 patients (73%) were treated with radiotherapy to the conserved breast, and 13/48 (27%) with observation. Patients who had IBR had better 5 year local recurrence free survival (LRFS) (84% versus 34%, p<0.001), and relapse free survival (RFS) (64% versus 34%, p=0.05), but no difference in overall survival (OS) (84% versus 85%, p=0.2). There was no difference in 5 year LRFS (80% versus 90%: p=0.3) between patients who received radiation of 50 Gy in 25 fractions versus ≥60 Gy. CONCLUSION: Patients with OPBC should be managed with IBR and breast conservation, or mastectomy. Our data suggest it is not necessary to irradiate the breast to more than 50 Gy in 25 fractions..
Kirby, A.M.
Coles, C.E.
Yarnold, J.R.
(2010). Target volume definition for external beam partial breast radiotherapy: clinical, pathological and technical studies informing current approaches. Radiother oncol,
Vol.94
(3),
pp. 255-263.
show abstract
Partial breast irradiation (PBI) is currently under investigation in several phase III trials and, following a recent consensus statement, its use off-study may increase despite ongoing uncertainty regarding optimal target volume definition. We review the clinical, pathological and technical evidence for target volume definition in external beam partial breast irradiation (EB-PBI). The optimal method of tumour bed (TB) delineation requires X-ray CT imaging of implanted excision cavity wall markers. The definition of clinical target volume (CTV) as TB plus concentric 15 mm margins is based on the anatomical distribution of multifocal and multicentric disease around the primary tumour in mastectomy specimens, and the clinical locations of local tumour relapse (LR) after breast conservation surgery. If the majority of LR originate from foci of residual invasive and/or intraduct disease in the vicinity of the TB after complete microscopic resection, CTV margin logically takes account of the position of primary tumour within the surgical resection specimen. The uncertain significance of independent primary tumours as sources of preventable LR, and of wound healing responses in stimulating LR, increases the difficulties in defining optimal CTV. These uncertainties may resolve after long-term follow-up of current PBI trials. By contrast, a commonly used 10mm clinical to planning target volume (PTV) margin has a stronger evidence base, although departmental set-up errors need to be confirmed locally. A CTV-PTV margin >10mm may be required in women with larger breasts and/or large seromas, whilst the role of image-guided radiotherapy with or without TB markers in reducing CTV-PTV margins needs to be explored..
Kirby, A.M.
Evans, P.M.
Nerurkar, A.Y.
Desai, S.S.
Krupa, J.
Devalia, H.
della Rovere, G.Q.
Harris, E.J.
Kyriakidou, J.
Yarnold, J.R.
(2010). How does knowledge of three-dimensional excision margins following breast conservation surgery impact upon clinical target volume definition for partial-breast radiotherapy?. Radiother oncol,
Vol.94
(3),
pp. 292-299.
show abstract
BACKGROUND AND PURPOSE: To compare partial-breast clinical target volumes generated using a standard 15 mm margin (CTV(standard)) with those generated using three-dimensional surgical excision margins (CTV(tailored 30)) in women who have undergone wide local excision (WLE) for breast cancer. MATERIAL AND METHODS: Thirty-five women underwent WLE with placement of clips in the anterior, deep and coronal excision cavity walls. Distances from tumour to each of six margins were measured microscopically. Tumour bed was defined on kV-CT images using clips. CTV(standard) was generated by adding a uniform three-dimensional 15 mm margin, and CTV(tailored 30) was generated by adding 30 mm minus the excision margin in three-dimensions. Concordance between CTV(standard) and CTV(tailored 30) was quantified using conformity (CoI), geographical-miss (GMI) and normal-tissue (NTI) indices. An external-beam partial-breast irradiation (PBI) plan was generated to cover 95% of CTV(standard) with the 95% isodose. Percentage-volume coverage of CTV(tailored 30) by the 95% isodose was measured. RESULTS: Median (range) coronal, superficial and deep excision margins were 15.0 (0.5-76.0)mm, 4.0 (0.0-60.0)mm and 4.0 (0.5-35.0)mm, respectively. Median CoI, GMI and NTI were 0.62, 0.16 and 0.20, respectively. Median coverage of CTV(tailored 30) by the PBI-plan was 97.7% (range 84.9-100.0%). CTV(tailored 30) was inadequately covered by the 95% isodose in 4/29 cases. In three cases, the excision margin in the direction of inadequate coverage was
Kirby, A.M.
Evans, P.M.
Donovan, E.M.
Convery, H.M.
Haviland, J.S.
Yarnold, J.R.
(2010). Prone versus supine positioning for whole and partial-breast radiotherapy: a comparison of non-target tissue dosimetry. Radiother oncol,
Vol.96
(2),
pp. 178-184.
show abstract
PURPOSE: To compare non-target tissue (including left-anterior-descending coronary-artery (LAD)) dosimetry of prone versus supine whole (WBI) and partial-breast irradiation (PBI). METHODS AND MATERIALS: Sixty-five post-lumpectomy breast cancer patients underwent CT-imaging supine and prone. On each dataset, the whole-breast clinical-target-volume (WB-CTV), partial-breast CTV (tumour-bed + 15 mm), ipsilateral-lung and chest-wall were outlined. Heart and LAD were outlined in left-sided cases (n=30). Tangential-field WBI and PBI plans were generated for each position. Mean LAD, heart, and ipsilateral-lung doses (x(mean)), maximum LAD (LAD(max)) doses, and the volume of chest-wall receiving 50 Gy (V(50Gy)) were compared. RESULTS: Two-hundred and sixty plans were generated. Prone positioning reduced heart and LAD doses in 19/30 WBI cases (median reduction in LAD(mean)=6.2 Gy) and 7/30 PBI cases (median reduction in LAD(max)=29.3 Gy) (no difference in 4/30 cases). However, prone positioning increased cardiac doses in 8/30 WBI (median increase in LAD(mean)=9.5 Gy) and 19/30 PBI cases (median increase in LAD(max)=22.9 Gy) (no difference in 3/30 cases). WB-CTV>1000cm(3) was associated with improved cardiac dosimetry in the prone position for WBI (p=0.04) and PBI (p=0.04). Prone positioning reduced ipsilateral-lung(mean) in 65/65 WBI and 61/65 PBI cases, and chest-wall V(50Gy) in all WBI cases. PBI reduced normal-tissue doses compared to WBI in all cases, regardless of the treatment position. CONCLUSIONS: In the context of tangential-field WBI and PBI, prone positioning is likely to benefit left-breast-affected women of larger breast volume, but to be detrimental in left-breast-affected women of smaller breast volume. Right-breast-affected women are likely to benefit from prone positioning regardless of breast volume..
Kirby, A.M.
Evans, P.M.
Haviland, J.
Yarnold, J.R.
(2009). Left Anterior Descending Coronary Artery (LAD) Doses from Breast Radiotherapy: is Prone Treatment Beneficial?. Clinical oncology,
Vol.21
(3),
pp. 251-2.
Kirby, A.M.
deSouza, N.M.
Evans, P.M.
Yarnold, J.R.
(2009). MRI Delineation of Tumour Bed for Partial Breast Irradiation: Fusion/Comparison with CT/Titanium Clip-based Method. Clinical oncology,
Vol.21
(3),
pp. 251-1.
Kirby, A.M.
Yarnold, J.R.
Evans, P.M.
Morgan, V.A.
Schmidt, M.A.
Scurr, E.D.
desouza, N.M.
(2009). Tumor bed delineation for partial breast and breast boost radiotherapy planned in the prone position: what does MRI add to X-ray CT localization of titanium clips placed in the excision cavity wall?. Int j radiat oncol biol phys,
Vol.74
(4),
pp. 1276-1282.
show abstract
PURPOSE: To compare tumor bed (TB) volumes delineated using magnetic resonance imaging plus computed tomography and clips (MRCT) with those delineated using CT and clips (CT/clips) alone in postlumpectomy breast cancer patients positioned prone and to determine the value of MRCT for planning partial breast irradiation (PBI). METHODS AND MATERIALS: Thirty women with breast cancer each had 6 to 12 titanium clips secured in the excision cavity walls at lumpectomy. Patients underwent CT imaging in the prone position, followed by MRI (T(1)-weighted [standard and fat-suppressed] and T(2)-weighted sequences) in the prone position. TB volumes were delineated separately on CT and on fused MRCT datasets. Clinical target volumes (CTV) (where CTV = TB + 15 mm) and planning target volumes (PTV) (where PTV = CTV + 10 mm) were generated. Conformity indices between CT- and MRCT-defined target volumes were calculated (ratio of the volume of agreement to total delineated volume). Discordance was expressed as a geographical miss index (GMI) (where the GMI = the fraction of total delineated volume not defined by CT) and a normal tissue index (the fraction of total delineated volume designated as normal tissue on MRCT). PBI dose distributions were generated to cover CT-defined CTV (CTV(CT)) with >or=95% of the reference dose. The percentage of MRCT-defined CTV (CTV(MRCT)) receiving >or=95% of the reference dose was measured. RESULTS: Mean conformity indices were 0.54 (TB), 0.84 (CTV), and 0.89 (PTV). For TB volumes, the GMI was 0.37, and the NTI was 0.09. Median percentage volume coverage of CTV(CT) was 97.1% (range, 95.3%-100.0%) and of CTV(MRCT) was 96.5% (range, 89.0%-100.0%). CONCLUSIONS: Addition of MR to CT/clip data generated TB volumes that were discordant with those based on CT/clips alone. However, clinically satisfactory coverage of CTV(MRCT) by CTV(CT)-based tangential PBI fields provides support for CT/clip-based TB delineation remaining the method of choice for PBI/breast boost radiotherapy planned using tangential fields..
Kirby, A.M.
George Mikhaeel, N.
(2007). The role of FDG PET in the management of lymphoma: practical guidelines. Nuclear medicine communications,
Vol.28
(5),
pp. 355-357.
Kirby, A.M.
Mikhaeel, N.G.
(2007). The role of FDG PET in the management of lymphoma: what is the evidence base?. Nuclear medicine communications,
Vol.28
(5),
pp. 335-354.
Kirby, A.M.
A'Hern, R.P.
D'Ambrosio, C.
Tanay, M.
Syrigos, K.N.
Rogers, S.J.
Box, C.
Eccles, S.A.
Nutting, C.M.
Harrington, K.J.
(2006). Gefitinib (ZD1839, Iressa(TM)) as palliative treatment in recurrent or metastatic head and neck cancer. British journal of cancer,
Vol.94
(5),
pp. 631-6.
Coles, C.
Griffin, C.
Kirby, A.
Titley, J.
Agrawal, R.
Alhasso, A.
Bhattacharya, I.
Brunt, M.
Ciurlionis, L.
Chan, C.
Donovan, E.
Emson, M.
Harnett, A.
Haviland, J.
Hopwood, P.
Jefford, M.
Kaggwa, R.
Sawyer, E.
Syndikus, I.
Tsang, Y.
Wheatley, D.
Wilcox, M.
Yarnold, J.
Bliss, J.
Partial breast radiotherapy after breast conservation surgery for early breast cancer: 5-year outcomes from the IMPORT LOW (CRUK/06/003) phase III randomised controlled trial. The lancet,
.
Gothard, L.
Edmunds, D.
Khabra, K.
Kirby, A.
Poonam, M.
McNair, H.
Roberts, D.
Symonds-Tayler, R.
Donovan, E.
Low-cost Kinect Version 2 imaging system for breath hold monitoring and gating: Proof of concept study for breast cancer VMAT radiotherapy. Journal of applied clinical medical physics,
.
Edmunds, D.
Gothard, L.
Khabra, K.
Kirby, A.
Madhale, P.
McNair, H.
Roberts, D.
Symonds-Tayler, R.
Donovan, E.
Low-cost Kinect Version 2 imaging system for breath hold monitoring and gating: Proof of concept study for breast cancer VMAT radiotherapy. Journal of applied clinical medical physics,
.
Kirby, A.M.
Updated ASTRO guidelines on accelerated partial breast irradiation (APBI): to whom can we offer APBI outside a clinical trial?. The british journal of radiology,
,
pp. 20170565-20170565.
Bagenal, J.
Roche, N.
Ross, G.
Kirby, A.
Dodwell, D.
Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation surgery?. Bmj,
,
pp. k1410-k1410.
Groot Koerkamp, M.L.
Vasmel, J.E.
Russell, N.S.
Shaitelman, S.F.
Anandadas, C.N.
Currey, A.
Vesprini, D.
Keller, B.M.
De-Colle, C.
Han, K.
Braunstein, L.Z.
Mahmood, F.
Lorenzen, E.L.
Philippens, M.E.
Verkooijen, H.M.
Lagendijk, J.J.
Houweling, A.C.
van den Bongard, H.J.
Kirby, A.M.
Optimizing MR-Guided Radiotherapy for Breast Cancer Patients. Frontiers in oncology,
Vol.10.
Ranger, A.
Dunlop, A.
Grimwood, A.
Durie, E.
Donovan, E.
Havilland, J.
Harris, E.
McNair, H.
Kirby, A.M.
Voluntary versus ABC breath-hold in the context of VMAT for breast and locoregional lymph node radiotherapy including the internal mammary chain. Clinical and translational radiation oncology,
Vol.27,
pp. 164-168.
show abstract
Background Deep-inspiration breath-hold (DIBH) reduces radiation dose to the heart in patients undergoing locoregional breast radiotherapy. In the context of tangential irradiation of the breast/ chest wall, a voluntary breath hold (vDIBH) technique has been shown to be as reproducible as a machine-assisted breath hold technique using the active breathing co-ordinator (ABC™, Elekta, Crawley, UK, ABC_DIBH). This study compares set-up reproducibility for vDIBH versus ABC_DIBH in patients undergoing volumetric-modulated arc radiotherapy (VMAT) for breast cancer, both with and without wax bolus.Method Patients with breast cancer requiring pan regional lymph node VMAT +/- wax bolus in breath-hold were CT scanned in vDIBH and ABC_DIBH. Patients were randomised to receive one technique for fractions 1-7 and the other for fractions 8-15. Daily cone beam computed tomography (CBCT) was performed and registered to planning-CT using bony anatomy. Within-patient comparisons of mean daily chest wall position were made using a paired t -test. Population, systematic (∑) and random errors (α) were estimated. Intrafraction reproducibility was assessed by comparing chest wall position and diaphragm movement between consecutive breath holds on CBCT.Results 16 patients were recruited. All completed treatment with both techniques (9 patients with wax bolus, 7 patients without). CBCT derived ∑ were 2.1-6.4 mm (ABC_DIBH) and 2.1-4.9 mm (vDIBH), α were 1.7-2.6 mm (ABC_DIBH) and 2.2-2.7 mm (vDIBH) and mean daily chest wall displacements (MD) were 0.0-1.5 mm (ABC_DIBH) and - 0.1-1.6 vDIBH (all p non-significant). Chest wall and diaphragm position was equivalent between consecutive breath holds in ABC and vDIBH (median difference 1.0 mm and 0.8 mm respectively, non p significant) demonstrating equivalent intrafraction reproducibility.Conclusion This study demonstrates that a simple voluntary breath hold technique is feasible in combination with VMAT (+/- bolus) and is as reproducible as ABC_DIBH with VMAT for the irradiation of the breast and axillary and IMC lymph nodes in breast cancer patients..
Stick, L.B.
Lorenzen, E.L.
Yates, E.S.
Anandadas, C.
Andersen, K.
Aristei, C.
Byrne, O.
Hol, S.
Jensen, I.
Kirby, A.M.
Kirova, Y.M.
Marrazzo, L.
Matías-Pérez, A.
Nielsen, M.M.
Nissen, H.D.
Oliveros, S.
Verhoeven, K.
Vikström, J.
Offersen, B.V.
Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy. Clinical and translational radiation oncology,
Vol.27,
pp. 126-131.
show abstract
Background and purpose Adjuvant radiotherapy of internal mammary nodes (IMN) improves survival in high-risk early breast cancer patients but inevitably leads to more dose to heart and lung. Target coverage is often compromised to meet heart/lung dose constraints. We estimate heart and lung dose when target coverage is not compromised in consecutive patients. These estimates are used to guide the choice of selection criteria for the randomised Danish Breast Cancer Group (DBCG) Proton Trial.Materials and methods 179 breast cancer patients already treated with loco-regional IMN radiotherapy from 18 European departments were included. If the clinically delivered treatment plan did not comply with defined target coverage requirements, the plan was modified retrospectively until sufficient coverage was reached. The choice of selection criteria was based on the estimated number of eligible patients for different heart and lung dose thresholds in combination with proton therapy capacity limitations and dose-response relationships for heart and lung.Results Median mean heart dose was 3.0 Gy (range, 1.1-8.2 Gy) for left-sided and 1.4 Gy (0.4-11.5 Gy) for right-sided treatment plans. Median V17Gy/V20Gy (hypofractionated/normofractionated plans) for ipsilateral lung was 31% (9-57%). The DBCG Radiotherapy Committee chose mean heart dose ≥ 4 Gy and/or lung V17Gy/V20Gy ≥ 37% as thresholds for inclusion in the randomised trial. Using these thresholds, we estimate that 22% of patients requiring loco-regional IMN radiotherapy will be eligible for the trial.Conclusion The patient selection criteria for the DBCG Proton Trial are mean heart dose ≥ 4 Gy and/or lung V17Gy/V20Gy ≥ 37%..
Slotman, B.J.
Cremades, V.
Kirby, A.M.
Ricardi, U.
European radiation oncology after one year of COVID-19 pandemic. Clinical and translational radiation oncology,
Vol.28,
pp. 141-143.
Somaiah, N.
Brunt, A.M.
Haviland, J.S.
Kirby, A.M.
Wheatley, D.
Bliss, J.
Yarnold, J.R.
5-fraction radiotherapy for breast cancer: FAST Forward to implementation. Clinical oncology,
.
Brunt, A.M.
Haviland, J.S.
Kirby, A.M.
Somaiah, N.
Wheatley, D.A.
Bliss, J.M.
Yarnold, J.R.
Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation. Clinical oncology (royal college of radiologists (great britain)),
Vol.33
(7),
pp. 430-439.
show abstract
Introduction The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in 4000 patients. We discuss concerns raised by the radiotherapy community in relation to implementing this schedule.Ipsilateral breast tumour relapse (ibtr) Published estimated 5-year IBTR with 95% CI after 40 Gy in 15 fractions was 2.1% (95% CI 1.4-3.1), 1.7% (1.2-1.6) after 27 Gy and 1.4% (0.2-2.2) after 26 Gy, emphatically showing non-inferiority of the 5-fraction regimens. Subgroup analyses comparing IBTR in 26 Gy versus 40 Gy show no evidence of differential effect regarding age, grade, pathological tumour size, nodal status, tumour bed boost, adjuvant chemotherapy, HER2 status and triple negative status. The number of events in these analyses is small and results should be interpreted with caution. There was only 1 IBTR event post-mastectomy.Normal tissue effects The 26 Gy schedule, on the basis of similar NTE to 40 Gy in 15 fractions, is the recommended regimen for clinical implementation. There is a low absolute rate of moderate/marked NTE, these are predominantly moderate not severe change. Subgroup analyses comparing clinician-assessed moderate or marked adverse effect for 26 Gy versus 40 Gy show no evidence of differential effects according to age, breast size, surgical deficit, tumour bed boost, or adjuvant chemotherapy.Radiobiological considerations The design of the FAST-Forward trial does not control for time-related effects, and the ability to interpret clinical outcomes in terms of underlying biology is limited. There could conceivably be a time-effect for tumour control. A slight reduction in α/β estimate for the late normal tissue effects of test regimens might be a chance effect, but if real could reflect fewer consequential late effects due to lower rates of moist desquamation.Conclusion The 26 Gy 5-fraction daily regimen for breast radiotherapy can be implemented now..
Yarnold, J.R.
Brunt, A.M.
Chatterjee, S.
Somaiah, N.
Kirby, A.M.
From 25 Fractions to Five: How Hypofractionation has Revolutionised Adjuvant Breast Radiotherapy. Clinical oncology (royal college of radiologists (great britain)),
Vol.34
(5),
pp. 332-339.
show abstract
There is a sound empirical basis for hypofractionation in radiotherapy for breast cancer. This article reviews the radiobiological implications of hypofractionation in breast cancer derived from a series of clinical trials that began when 50 Gy in 25 fractions over 5 weeks was commonplace. These trials led first to 40 Gy in 15 fractions over 3 weeks and, subsequently, to 26 Gy in five fractions over 1 week being adopted as standards of care for many patients prescribed whole- or partial-breast radiotherapy after primary surgery..
Brand, D.H.
Kirby, A.M.
Yarnold, J.R.
Somaiah, N.
How Low Can You Go? The Radiobiology of Hypofractionation. Clinical oncology (royal college of radiologists (great britain)),
Vol.34
(5),
pp. 280-287.
show abstract
Hypofractionated radical radiotherapy is now an accepted standard of care for tumour sites such as prostate and breast cancer. Much research effort is being directed towards more profoundly hypofractionated (ultrahypofractionated) schedules, with some reaching UK standard of care (e.g. adjuvant breast). Hypofractionation exerts varying influences on each of the major clinical end points of radiotherapy studies: acute toxicity, late toxicity and local control. This review will discuss these effects from the viewpoint of the traditional 5 Rs of radiobiology, before considering non-canonical radiobiological effects that may be relevant to ultrahypofractionated radiotherapy. The principles outlined here may assist the reader in their interpretation of the wealth of clinical data presented in the tumour site-specific articles in this special issue..